Eloralintide for Adults With Obesity Who Still Carry Excess Weight on a Weekly Incretin
Tests eloralintide against placebo in adults with obesity already taking a weekly incretin.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Key facts
- Where
- Atlantis, Birmingham, Boston, Bridgeport, Chapel Hill, Chesterfield, Chicago, Cincinnati, Columbia, Dallas, Doral, Dunwoody, Fleming Island, Gainesville, Greensboro, Houston, Idaho Falls, Irvine, Jacksonville, Kingwood, La Jolla, La Mesa, Lexington, Lima, Miami, Mission, Missouri City, Monroe, Morehead City, Myrtle Beach, New Haven, New York, Phoenix, Pittsburgh, Rolling Hills Estates, Sacramento, Saint Augustine, San Antonio, San Diego, Santa Ana, Scottsdale, Shavano Park, Southfield, Topeka, Troy, Tucson, Tustin, Waltham, Waterbury, Weslaco, West Des Moines, West Palm Beach, Wilmington, and Wylie, United StatesSee the 58 sites
- Phase
- Phase 3
Where in United States
- JEM Research InstituteAtlantis, United StatesTaking people
- Birmingham Clinical ResearchBirmingham, United StatesTaking people
- Brigham and Women's Hospital Diabetes ProgramBoston, United StatesTaking people
- New England Research Associates, LLCBridgeport, United StatesTaking people
- University of North Carolina Medical CenterChapel Hill, United StatesTaking people
- Clinical Research ProfessionalsChesterfield, United StatesTaking people
- Great Lakes Clinical Trials - RavenswoodChicago, United StatesTaking people
- CTI Clinical Research CenterCincinnati, United StatesTaking people
- Centennial Medical GroupColumbia, United StatesTaking people
- UT Southwestern Medical CenterDallas, United StatesTaking people
- AMR ClinicalDoral, United StatesTaking people
- Teak Research Consults - DunwoodyDunwoody, United StatesTaking people
- Northeast Research Institute (NERI)Fleming Island, United StatesTaking people
- Center for Advanced Research & EducationGainesville, United StatesTaking people
- Medication ManagementGreensboro, United StatesTaking people
- Juno ResearchHouston, United StatesTaking people
- Family First Medical CenterIdaho Falls, United StatesTaking people
- Irvine Clinical ResearchIrvine, United StatesTaking people
- Jacksonville Center for Clinical ResearchJacksonville, United StatesTaking people
- Activian Clinical ResearchKingwood, United StatesTaking people
- Scripps Whittier Diabetes InstituteLa Jolla, United StatesTaking people
- EndoTrials Center for Clinical ResearchLa Mesa, United StatesNot yet recruiting
- AMR ClinicalLexington, United StatesTaking people
- Care Access - LimaLima, United StatesTaking people
- New Horizon Research CenterMiami, United StatesTaking people
- Texas Valley Clinical Research (TVCR) - MissionMission, United StatesTaking people
- Synergy Groups Medical LLC - Missouri CityMissouri City, United StatesTaking people
- IMA Clinical Research Monroe-MainMonroe, United StatesTaking people
- Carteret Medical GroupMorehead City, United StatesTaking people
- Trial Management AssociatesMyrtle Beach, United StatesNot yet recruiting
- Yale University School Of MedicineNew Haven, United StatesTaking people
- Ima Clinical Research ManhattanNew York, United StatesTaking people
- NYU Langone HealthNew York, United StatesTaking people
- Weill Cornell Medical CollegeNew York, United StatesTaking people
- RIO Clinical Trials - PhoenixPhoenix, United StatesTaking people
- Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)Pittsburgh, United StatesTaking people
- Peninsula Research AssociatesRolling Hills Estates, United StatesTaking people
- Care Access - SacramentoSacramento, United StatesNot yet recruiting
- St. Johns Center for Clinical ResearchSaint Augustine, United StatesTaking people
- Endeavor Clinical TrialsSan Antonio, United StatesTaking people
- IMA Clinical Research San AntonioSan Antonio, United StatesTaking people
- Artemis Institute for Clinical ResearchSan Diego, United StatesTaking people
- Southern California Clinical ResearchSanta Ana, United StatesTaking people
- Headlands Research - ScottsdaleScottsdale, United StatesTaking people
- Consano Clinical Research, LLCShavano Park, United StatesTaking people
- Great Lakes Research InstituteSouthfield, United StatesTaking people
- Revive Research Institute, IncSouthfield, United StatesTaking people
- Cotton O'Neil Diabetes & EndocrinologyTopeka, United StatesTaking people
- Arcturus Healthcare , PLC, Troy Internal Medicine Research DivisionTroy, United StatesTaking people
- Novak Clinical Research - Tucson - North La Cholla BoulevardTucson, United StatesTaking people
- University Clinical Investigators, Inc.Tustin, United StatesTaking people
- MedVadis Research CorporationWaltham, United StatesTaking people
- Chase Medical Research, LLCWaterbury, United StatesTaking people
- Texas Valley Clinical ResearchWeslaco, United StatesTaking people
- Iowa Diabetes and Endocrinology Research CenterWest Des Moines, United StatesTaking people
- Metabolic Research Institute, IncWest Palm Beach, United StatesTaking people
- Accellacare - Wilmington - 1917 Tradd CourtWilmington, United StatesTaking people
- Medrasa Clinical ResearchWylie, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07392190EU 2025-523659-73-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Inclusion: Are on stable incretin therapy at screening; With persistent obesity or overweight defined as:; ≥30 kg/m2 OR; ≥27 kg/m2 with at least one existing obesity related complication at screening:; hypertension; dyslipidemia; obstructive sleep apnea; cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or; type 2 diabetes; Have a stable body weight (<5% body weight change) at screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have taken any of the following antihyperglycemic medications within 90 days before screening:; dipeptidyl peptidase-4 (DPP-4) inhibitors; amylin analogs; insulin; Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.